Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.

Mandosi E, Fallarino M, Gatti A, Carnovale A, Rossetti M, Lococo E, Buchetti B, Filetti S, Lenti L, Morano S.

J Atheroscler Thromb. 2010 Jun 30;17(6):539-45. Epub 2010 Feb 5.

2.

Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.

Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Herman ZS.

J Cardiovasc Pharmacol. 2005 Sep;46(3):377-86.

PMID:
16116345
3.

Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Chu CS, Lee KT, Lee MY, Su HM, Voon WC, Sheu SH, Lai WT.

Am J Cardiol. 2006 Mar 1;97(5):646-50. Epub 2006 Jan 9.

PMID:
16490430
4.

Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.

Castaño G, Mas R, Fernández L, Illnait J, Mesa M, Alvarez E, Lezcay M.

Drugs Aging. 2003;20(2):153-63.

PMID:
12534315
5.

Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.

Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Abad S, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S231-5.

6.

3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.

Wagner AH, Gebauer M, Güldenzoph B, Hecker M.

Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1784-9.

8.
10.

[The effects of atorvastatin on C-reactive protein induced Toll-like receptor 4 expression on CD14+ monocyte].

Peng L, Luo YT, Liu JL.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Jul;39(7):664-9. Chinese.

PMID:
22088250
11.

Modulating effect of atorvastatin on paraoxonase 1 activity in type 2 diabetic Egyptian patients with or without nephropathy.

Abdin AA, Hassanien MA, Ibrahim EA, El-Noeman Sel-D.

J Diabetes Complications. 2010 Sep-Oct;24(5):325-33. doi: 10.1016/j.jdiacomp.2009.04.001. Epub 2009 Jun 23.

PMID:
19553142
12.
13.

Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes.

Ichida Y, Hasegawa G, Fukui M, Obayashi H, Ohta M, Fujinami A, Ohta K, Nakano K, Yoshikawa T, Nakamura N.

Pharmacology. 2006;76(1):34-9. Epub 2005 Oct 14.

PMID:
16227702
14.

Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.

Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H.

Diabet Med. 2011 Jul;28(7):856-64. doi: 10.1111/j.1464-5491.2011.03240.x.

PMID:
21244474
15.

Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.

Dobreanu M, Dobreanu D, Fodor A, Bacarea A.

Rom J Intern Med. 2007;45(2):193-9.

PMID:
18333374
16.

Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.

Meas T, Laloi-Michelin M, Virally M, Peynet J, Giraudeaux V, Kévorkian JP, Guillausseau PJ.

Eur J Intern Med. 2009 Mar;20(2):197-200. doi: 10.1016/j.ejim.2008.06.009. Epub 2008 Aug 15.

PMID:
19327612
17.
18.

Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.

Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.

Transplant Proc. 2005 Nov;37(9):3808-12.

PMID:
16386546
19.

Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.

Santini SA, Carrozza C, Lulli P, Zuppi C, CarloTonolo G, Musumeci S.

J Atheroscler Thromb. 2003;10(3):160-4.

Supplemental Content

Support Center